Liver Cirrhosis, Experimental - Drug therapy
Research News and Information

Monday, November 23, 2009

Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis.

5 Oct 2009 AIM: To investigate the correlation between the antifibrotic effect of baicalin and serum cytokine production in rat hepatic fibrosis. METHODS: Forty male Sprague-Dawley rats were divided randomly into four groups: normal control group, model group, ... Read more...

Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis.

26 Sep 2009 AIM: To investigate the inhibitory effect of natural taurine (NTau) on portal hypertension (PHT) in rats with experimentally-induced liver cirrhosis (LC). METHODS: Experimentally-induced LC Wistar rats (20 rats/group) were treated with either oral ... Read more...

Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat.

12 Sep 2009 Ang-(1-7) (angiotensin-1-7), a peptide product of the recently described ACE (angiotensin-converting enzyme) homologue ACE2, opposes the harmful actions of AngII (angiotensin II) in cardiovascular tissues, but its role in liver disease is unknown. ... Read more...

Latest indexed articles for 'Liver Cirrhosis, Experimental - Drug therapy'

These are the very latest articles for this heading:

• Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. 5 Oct 2009
• Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis. 26 Sep 2009
• Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. 12 Sep 2009
• Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. 21 Apr 2009
• Accelerative effect of leflunomide on recovery from hepatic fibrosis involves TRAIL-mediated hepatic stellate cell apoptosis. 8 Apr 2009
• Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate. 21 Mar 2009
• Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. 12 Jan 2009
• Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats. 16 Nov 2008
• Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. 16 Nov 2008
• Action mechanism of Yi Guan Jian Decoction on CCl4 induced cirrhosis in rats. 16 Oct 2008
• [Curative effect of interferon-alpha on rat liver fibrosis induced by CCl4] 29 Sep 2008
• Functional hepatic recovery after xenotransplantation of cryopreserved fetal liver cells or soluble cell-factor administration in a cirrhotic rat model: are viable cells necessary? 25 Aug 2008
• Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. 18 Jul 2008
• Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. 30 Jun 2008
• [Effect of peptide YY on hepatic fibrosis in rats] 29 Jun 2008
• Enhanced actions of insulin-like growth factor-I and interferon-alpha co-administration in experimental cirrhosis. 7 Jun 2008
• Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. 12 May 2008
• Hepatoprotective effect of water soluble extract of Coleus barbatus on cholestasis on young rats. 29 Apr 2008
• Role of N-acetylcysteine on fibrosis and oxidative stress in cirrhotic rats. 30 Mar 2008
• N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome. 30 Mar 2008

See a longer list of these articles.

Technical information about 'Liver Cirrhosis, Experimental'

Definition: Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.

Descriptor UI: D008106

Alternative terms: Liver Cirrhosis, Experimental; Cirrhosis, Experimental Liver; Liver Cirrhoses, Experimental; Experimental Liver Cirrhosis; Hepatic Cirrhosis, Experimental; Experimental Hepatic Cirrhosis; Cirrhoses, Experimental Liver; Experimental Liver Cirrhoses;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; urine; veterinary; ultrasonography; virology;

Tree Number: C06.552.630.467; E05.598.500.468;

Technical Notes: DF: LIVER CIRRHOSIS EXPER